The Academy of Technology and Engineering’s (ATSE) Innovation and Excellence Awards for 2020 announced SpeeDx founders Dr Alison Todd and Dr Elisa Mokany winners of the Clunies Ross Award for...
The pandemic environment of COVID-19 has shined a spotlight on the importance of clinical diagnostics. Now, more than ever, the growth and success of SpeeDx has global reach in terms...
SpeeDx has partnered with Roche, a global pioneer in pharmaceuticals and diagnostics, to expand access to infectious disease and antibiotic resistance tests and technology. Under the terms of the agreement,...
The Therapeutic Goods Administration (TGA) have cleared ResistancePlus® MG FleXible for the Cepheid GeneXpert® System, and it is now available for sale in Australia. This announcement further expands access to...
ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers...
The Australian Research Council (ARC) awarded almost $5 million to a collaboration with SpeeDx and over 20 other organisations, for the formation of an Industrial Transformation Research Hub to Combat...
Researchers at The University of Western Australia and King Edward Memorial Hospital have teamed up with SpeeDx to commercialise a new low-cost test to identify women at risk of premature...
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets. SpeeDx collaborates with key researchers and organizations around the globe...
This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mycoplasma genitalium (Mgen). Current Canadian management guidelines...
SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials and new product development. "We welcome this extension of the utility...